Jonathan DiVincenzo, head of life sciences at EMD, has said that the deal improves the company’s flow cytometry range and will create “tremendous value for our customers’ research outcomes.” Amnis’ products are used in flow cytometry applications across various fields including biotech and pharmaceutical cell analysis.
DiVincenzo went on to add that “with this acquisition, EMD Millipore becomes the only provider of this technology.” David Basiji, Amnis chief executive, believes becoming park of Merck will “accelerate product development”for his company. The deal is expected to go through in the final quarter of this year.
Looking for a job in the science industry? Start by clicking here, now